Replies to post #1017 on Idenix Pharmaceuticals (IDIX)

[gofishmarko]

>> The "creative approach" is quadruple therapy for partial responders to first-line SoC. I think this is clear from the MS webcast. <<


I didn't pick up on that but you're probably right.

Not quite as 'creative' as I had hoped but if they can make it happen I'll live with it.